Skip to main content

wegovy

6 articles found

NVO: GLP-1 Giant Falls to 10x Earnings on Lilly Fears

Novo Nordisk shares have collapsed to $37.45, a 59% decline from their 52-week high of $91.90, after the company's next-generation obesity drug CagriSema delivered clinical trial results that trailed Eli Lilly's Zepbound. The February 27 selloff alone erased 21% of the stock's value in a single session, marking the most dramatic repudiation of a GLP-1 leader since the obesity drug revolution began. At 10.3 times trailing earnings, Novo Nordisk now trades at a valuation that would be cheap for a utility company — let alone a pharmaceutical giant that generated DKK 308 billion ($44 billion) in revenue last year with 81% gross margins. The market cap has contracted to $166.5 billion, roughly half of where it stood six months ago. The question facing investors is whether the CagriSema disappointment is a fundamental thesis-breaker or whether the market has overreacted. Novo Nordisk still dominates the GLP-1 market alongside Eli Lilly, with Wegovy and Ozempic generating massive cash flows. But with the company guiding for a 5–13% decline in 2026 sales due to U.S. price compression, the near-term outlook is genuinely challenging. For context on how NVO reached this point, see our [earlier analysis of the 50% price reduction](/articles/nvo-analysis-novo-nordisks-50-price-slash-creates-a-deep-value-puzzle-for-glp-1-investors) that preceded this latest crash.

NVONovo NordiskGLP-1

NVO: Novo Nordisk's 50% Price Slash Creates a Deep-Value

Novo Nordisk (NVO) has gone from the world's most valuable healthcare company to a deep-value opportunity in the span of twelve months. Shares closed at $38.16 on February 25, 2026 — down 59% from their 52-week high of $93.80 and trading at just 10.5x trailing earnings. The Danish pharmaceutical giant hit a fresh 52-week low of $37.65 during today's session on volume 2.6 times the daily average, as investors digested the company's announcement that it will cut U.S. list prices on Ozempic and Wegovy by up to 50% starting in 2027. The price cuts represent a strategic pivot that could reshape the entire GLP-1 market. For years, Novo Nordisk and rival Eli Lilly have commanded premium pricing for their obesity and diabetes drugs — Ozempic and Wegovy carry U.S. list prices above $1,000 per month. By voluntarily halving prices, Novo is betting that volume gains from dramatically expanded insurance coverage and patient access will more than offset the per-unit revenue decline. It is a gamble that pits near-term margin compression against long-term market dominance. For investors, the question is straightforward: does a sub-11x P/E ratio adequately compensate for the margin headwinds ahead, or is the selloff a classic overreaction that creates a generational entry point into the world's dominant GLP-1 franchise? The answer lies in Novo's financial fundamentals, its competitive moat, and whether the company's massive manufacturing investments can deliver the scale needed to make lower prices profitable.

NVONovo NordiskOzempic

Novo Nordisk Slashes Ozempic and Wegovy Prices by 50%

Novo Nordisk dropped a bombshell on the pharmaceutical industry this week, announcing plans to cut the U.S. list prices of its blockbuster GLP-1 drugs — Wegovy, Ozempic, and Rybelsus — by up to 50% starting January 1, 2027. The new uniform list price of $675 per month, down from current prices ranging between $1,027 and $1,350, marks the most aggressive pricing move yet in the rapidly evolving obesity and diabetes drug market. The announcement sent Novo Nordisk shares tumbling to a fresh 52-week low of $37.65, extending a brutal decline that has erased roughly 75% of the stock's value since its mid-2024 peak. The price cuts arrive at a moment of acute vulnerability for the Danish drugmaker. Just days earlier, Novo reported disappointing results from its REDEFINE 4 trial pitting next-generation drug CagriSema against Eli Lilly's tirzepatide (Zepbound), sending shares down over 16% in a single session. With its market capitalization now sitting at roughly $169 billion — down from north of $600 billion at its zenith — Novo Nordisk is attempting a high-stakes pivot: sacrificing near-term pricing power to defend market share against an increasingly dominant Eli Lilly and a swarm of pharma giants preparing to enter the weight-loss arena. The implications extend far beyond one company's balance sheet. Novo's decision reshapes the economics of a drug category projected to exceed $150 billion in annual sales by the end of the decade, puts immediate pressure on Eli Lilly to respond, and could dramatically expand the patient population with affordable access to GLP-1 therapies. For investors, the question is whether this is a desperate retreat or a calculated long-term play.

Novo NordiskGLP-1 drugsOzempic price cut

Novo Nordisk Slashes Ozempic and Wegovy Prices by Up to 50%

Novo Nordisk dropped a bombshell on Tuesday, announcing it will slash the U.S. list prices of its blockbuster weight-loss and diabetes drugs — Wegovy, Ozempic, and Rybelsus — by up to 50% starting January 1, 2027. All three treatments will carry a new list price of $675 per month, down from approximately $1,350 for Wegovy and $1,027 for the diabetes drugs. The move is specifically designed to relieve the cost burden on insured patients with high-deductible health plans or coinsurance benefit structures. The announcement lands at perhaps the worst possible moment for the Danish pharmaceutical giant. Just one day earlier, shares cratered 16% after Novo's next-generation obesity drug CagriSema failed to demonstrate non-inferiority against Eli Lilly's Zepbound in the pivotal REDEFINE-4 phase III trial. The double blow has sent NVO shares tumbling to $38.58 — a new 52-week low — erasing more than half its market capitalization from last year's peak of $93.80. The stock is now down nearly 59% from its highs, and trading at its lowest P/E ratio in years at just 10.5x earnings. For investors, the twin developments crystallize a question that has been building for months: Is Novo Nordisk ceding the GLP-1 weight-loss throne to Eli Lilly, or is this a generational buying opportunity for one of pharma's most profitable franchises?

Novo NordiskOzempicWegovy

Novo Nordisk Crashes 47% From Peak as Obesity Drug Empire

Novo Nordisk, the Danish pharmaceutical giant that once seemed invincible atop the global obesity drug market, is now fighting on every front simultaneously — and investors are voting with their feet. Shares of Novo Nordisk (NVO) traded at $49.57 on Monday, down a staggering 47% from their 52-week high of $93.80, as the company grapples with intensifying competition from Eli Lilly, a legal war against compounding pharmacies, and a 2026 financial outlook that shocked Wall Street with the prospect of declining revenues. The scale of the reversal is remarkable. Just months ago, Novo was the most valuable company in Europe and the undisputed leader in GLP-1 weight loss treatments. Today, its market capitalization has been cut roughly in half to $220.4 billion, while rival Eli Lilly commands a valuation north of $932 billion — more than four times Novo's size. In the span of a single month, NVO shares plunged 21%, with a single-day drop of 14% followed by violent snapback rallies, as investors tried to parse whether the company's problems are temporary growing pains or signs of a structural decline. The catalyst for the latest rout was Novo's 2026 guidance, released alongside otherwise solid fourth-quarter results on February 4. While Q4 revenue came in at DKK 78.4 billion with a 34% net profit margin — numbers most companies would celebrate — the forward outlook told a different story entirely. On an adjusted basis, Novo expects sales and operating profit to decline 5% to 13% at constant exchange rates in 2026, a dramatic contrast to Eli Lilly's guidance calling for 25% sales growth in the same period.

Novo NordiskNVOEli Lilly

Analysis: Novo Nordisk Sues Hims & Hers Over Wegovy Copycats

The most explosive battle in the $100 billion GLP-1 drug market erupted into open warfare this week. Novo Nordisk filed a patent infringement lawsuit against Hims & Hers Health on Monday, seeking to permanently ban the telehealth company from selling compounded versions of its blockbuster weight-loss drug Wegovy. The lawsuit came just two days after Hims launched — and then abruptly pulled — a $49-per-month oral semaglutide pill that undercut Novo's FDA-approved Wegovy pill by roughly $100. The legal salvo, combined with a parallel FDA crackdown on compounded GLP-1 ingredients, has sent Hims & Hers stock into freefall. Shares plunged 16% on Monday and dropped another 5.4% on Tuesday to $18.29, bringing the total decline over the past month to approximately 40%. Hims now trades at $18.29 — a staggering 75% below its 52-week high of $72.98. Novo Nordisk, by contrast, rallied 3.6% on Monday and held steady Tuesday at $49.63, though the Danish giant has its own problems: its stock sits 47% below its own 52-week high of $93.80 amid fierce competition and disappointing 2026 guidance. This is no longer a skirmish over compounding pharmacies. It is a defining legal and regulatory showdown that will determine who controls access to the most lucrative class of drugs in a generation — and at what price 1.5 million Americans currently using compounded GLP-1s will pay for their treatment.

GLP-1 drugsNovo NordiskHims and Hers